Cell culture: nanomolar concentrations dominate
The largest body of GHK-Cu data is in vitro, and the concentration range that recurs most often is 1 to 100 nanomolar applied to cultured human dermal fibroblasts, lung fibroblasts, keratinocytes, or endothelial cells [1][2]. Effects on collagen, elastin, glycosaminoglycan, and matrix metalloproteinase expression are observed reproducibly in this range, with biological responses often peaking around 10 nanomolar [1][17]. The Pickart and Margolina 2018 transcriptomic review aggregates the data: 31.2 percent of protein-coding human genes shifted by 50 percent or more at these concentrations, with 59 percent upregulated and 41 percent downregulated [1]. Higher concentrations into the micromolar range have been used for anti-cancer mechanism studies, where GHK upregulates caspases in neuroblastoma cells [12].
Topical cosmetic formulations
Topical research formulations have used loadings from roughly 0.05 percent up to 2 percent w/w in creams, serums, gels, and nanolipid carriers. The Badenhorst 2016 anti-wrinkle study used a nanolipid carrier formulation twice daily for 8 weeks [7]. The Leyden 2002 study used a twice-daily cream over 12 weeks in 67 women [6]. The 2024 post-laser study referenced in the Adnan 2025 review used 0.05 percent GHK-Cu gel applied to laser-treated facial skin twice daily [13]. The general pattern is that topical research formulations target very low concentrations relative to the in vitro effective range — consistent with topical delivery that concentrates the active in the stratum corneum and upper dermis without flooding systemic circulation.
Murine wound dressings
The Chen 2025 GEK hydrogel paper used composite hydrogel applied topically to full-thickness dorsal wounds in male C57BL/6 mice (18-25g body weight), with the GHK-Cu loaded as part of the matrix [4]. The Arul 2007 diabetic-rat work used GHK-loaded collagen films laid directly on the wound [16]. In both cases the precise loading depends on the area of the wound and the carrier — these are not dose-by-weight studies but dressing studies, and the relevant exposure metric is local concentration at the wound bed, not systemic milligram-per-kilogram dose.
Rodent systemic: 20 mg/kg oral, 0.5 mcg/kg intraperitoneal
The 2025 Mao colitis study used 20 milligrams per kilogram body weight by daily oral gavage for 14 days in BALB/c mice, a notably high systemic dose relative to the cell-culture nanomolar range — chosen because oral bioavailability of a tripeptide is uncertain and intestinal first-pass exposure was the relevant site of action [3]. By contrast, rodent behavioral studies have used much smaller systemic doses: Bobyntsev 2015 administered 0.5 micrograms per kilogram intraperitoneally and saw anxiolytic-like effects in the elevated plus maze within 12 minutes [8]; Sever'yanova and Dolgintsev 2017 saw a 5-fold reduction in inter-male aggressive attacks at microgram-range intraperitoneal dosing [9]. The 4 to 5 orders of magnitude separating these systemic-dose studies is itself a finding — it suggests that very different exposure regimes target very different physiology.
Half-life and pharmacokinetic notes
Free GHK has a short plasma half-life on the order of minutes; the copper complex is more stable [1]. Endogenous plasma levels of approximately 200 nanograms per millilitre in young adults decline to roughly 80 nanograms per millilitre by age 60 — about a 60 percent reduction — which is the basis of the supplementation hypothesis that motivates much of the cosmetic literature [1]. Skin retention after topical application is on the order of hours to days depending on vehicle, with nanolipid carriers extending retention versus aqueous solutions [7].
Stability and formulation
GHK-Cu is highly stable as a dry powder under refrigeration. In aqueous solution, stability depends on pH and on copper-to-peptide stoichiometry: an acidic pH and a 1:1 Cu:peptide ratio give the most stable complex. The complex is photosensitive and oxidation-sensitive in solution, which is why many topical formulations include reducing agents or oxygen-impermeable packaging. Compounded injectable formulations have historically been prepared as lyophilized powders reconstituted at point of use, but the regulatory status of compounded injectable GHK-Cu is currently in flux following the April 2026 FDA Category 2 action [14].
What this page does not tell you
It does not tell you what dose to take, what to inject, or how to formulate anything for personal use. The studies summarized above tested specific concentrations in specific species via specific routes for specific endpoints. None of those study designs map cleanly onto a human individual outside of the controlled topical cosmetic literature. Anyone considering systemic GHK-Cu should also be aware that no FDA-approved injectable formulation exists, that no large randomized controlled human trial has been published, and that the recent FDA action on compounding bulks status leaves the legal landscape uncertain [14]. This site does not sell GHK-Cu, does not recommend GHK-Cu, and is not a clinic.